Antithrombotic agents reduce risk of thromboembolism in severely ill patients. Patients with
coronavirus disease 2019 (COVID‐19) may realize additional benefits from heparins …

Acute respiratory distress syndrome (ARDS) is a heterogeneous lung disease responsible
for significant morbidity and mortality among critically ill patients, including those infected …

Abstract Background: COVID-19–related acute illness is associated with an increased risk of
venous thromboembolism (VTE). Objective: These evidence-based guidelines from the …

Objective To assess the benefits and harms of different types and doses of anticoagulant
drugs for the prevention of venous thromboembolism in patients who are acutely ill and …

Purpose This executive summary of a national living guideline aims to provide rapid
evidence based recommendations on the role of drug interventions in the treatment of …

Hospital‐associated venous thromboembolism (HA‐VTE) is a major cause of morbidity and
mortality and is internationally recognized as a significant patient safety issue. While …

Background Deep vein thrombosis (DVT) is a common complication and the second leading
cause of death in cancer patients. Pro-inflammatory stimuli in the cancer microenvironment …

Inflammatory bowel disease (IBD), Crohn's disease and ulcerative colitis are chronic
inflammatory disorders of the intestines. The underlying inflammation activates the …

Venous thromboembolism (VTE) is considered a leading safety concern during
hospitalization. The Padua Predication Score (PPS) is a risk model conceived to predict VTE …

D-dimer assay's utility for excluding venous thromboembolism (VTE) in hospitalized patients
is debatable. We aimed to assess the current use of D-dimer as a diagnostic tool for …